

CITATION REPORT

List of articles citing

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA

DOI: 10.1186/s12977-015-0150-z
Retrovirology, 2015, 12, 22.

Source: <https://exaly.com/paper-pdf/62241593/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
173	CRISPR-Cas: From the Bacterial Adaptive Immune System to a Versatile Tool for Genome Engineering. 2015 , 54, 13508-14		17
172	CRISPR-Cas: von einem bakteriellen adaptiven Immunsystem zu einem vielseitigen Werkzeug für die Gentechnik. 2015 , 127, 13710-13716		4
171	Progress and Prospects of Anti-HBV Gene Therapy Development. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 17589-610	6.3	23
170	Cell-based gene therapy against HIV. 2015 , 22, 851-5		3
169	Experimental therapies in the neuronal ceroid lipofuscinoses. 2015 , 1852, 2292-300		25
168	CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. <i>Virologica Sinica</i> , 2015 , 30, 317-25	6.4	15
167	Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. 2015 , 494, 180-94		78
166	The latest science from the IAS Towards an HIV Cure Symposium. <i>Journal of Virus Eradication</i> , 2016 , 2, 235-241	2.8	1
165	Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors. <i>Viruses</i> , 2016 , 8,	6.2	1
164	A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures. 2016 , 17, 2819-2826		85
163	Toll-interacting protein inhibits HIV-1 infection and regulates viral latency. 2016 , 475, 161-8		4
162	Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. 2016 , 23, 690-5		120
161	CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. 2016 , 15, 481-489		171
160	Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases. 2016 , 71, 2089-99		4
159	Gene Editing for Treatment of Neurological Infections. 2016 , 13, 547-54		8
158	The clinical applications of genome editing in HIV. 2016 , 127, 2546-52		51
157	CRISPR/Cas9 system and its applications in human hematopoietic cells. 2016 , 62, 6-12		9

156	Antiviral therapy of persistent viral infection using genome editing. 2016 , 20, 85-91		9
155	Pseudorabies virus can escape from CRISPR-Cas9-mediated inhibition. 2016 , 223, 197-205		20
154	Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9. <i>Scientific Reports</i> , 2016 , 6, 29530	4.9	68
153	CRISPR-Cas9 technology and its application in haematological disorders. 2016 , 175, 208-225		15
152	Disruption or Excision of Provirus as an Approach to HIV Cure. 2016 , 30, 551-555		5
151	Clinical Applications of Genome Editing to HIV Cure. 2016 , 30, 539-544		7
150	The variances of Sp1 and NF- κ B elements correlate with the greater capacity of Chinese HIV-1 BTLTR for driving gene expression. <i>Scientific Reports</i> , 2016 , 6, 34532	4.9	17
149	Attacking HIV-1 RNA versus DNA by sequence-specific approaches: RNAi versus CRISPR-Cas. 2016 , 44, 1355-1365		16
148	Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy. 2016 ,		3
147	Cell and gene therapy strategies to eradicate HIV reservoirs. 2016 , 11, 442-9		17
146	CRISPR/Cas9: a double-edged sword when used to combat HIV infection. <i>Retrovirology</i> , 2016 , 13, 37	3.6	44
145	CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. 2016 , 24, 522-6		149
144	Using Engineered Nucleases to Create HIV-Resistant Cells. 2016 , 161-186		1
143	Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. 2016 , 30, 1163-74		47
142	Potential pitfalls of CRISPR/Cas9-mediated genome editing. 2016 , 283, 1218-31		151
141	Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure. 2016 , 67, 215-28		61
140	Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. 2016 , 24, 294-306		19
139	Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions. 2016 , 14, 177-91		4

138	Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. 2016 , 126, 90-8		35
137	Novel AIDS therapies based on gene editing. 2017 , 74, 2439-2450		15
136	A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. <i>Scientific Reports</i> , 2017 , 7, 41968	4-9	85
135	Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS. 2017 , 24, 377-384		25
134	Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans. 2017 , 25, 833-850		50
133	Exosomes in HIV infection: A review and critical look. 2017 , 53, 146-154		43
132	InVivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. 2017 , 25, 1168-1186		164
131	Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants. <i>Scientific Reports</i> , 2017 , 7, 14413	4-9	22
130	Genome editing technologies to fight infectious diseases. 2017 , 15, 1001-1013		9
129	Gene Therapy Blueprints for NeuroAIDS. 2017 , 953-993		1
128	Gene editing in T cell therapy. 2017 , 44, 415-422		13
127	Therapeutic Strategies of Clustered Regularly Interspaced Palindromic Repeats-Cas Systems for Different Viral Infections. 2017 , 30, 552-559		1
126	Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases. 2017 , 31, 883-895		7
125	Combinatorial CRISPR-Cas9 and RNA Interference Attack on HIV-1 DNA and RNA Can Lead to Cross-Resistance. 2017 , 61,		13
124	A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes. <i>Scientific Reports</i> , 2017 , 7, 5955	4-9	17
123	HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. 2017 , 31, 2035-2052		116
122	Fight fire with fire: Gene therapy strategies to cure HIV. 2017 , 15, 747-758		9
121	Exploring the potential of genome editing CRISPR-Cas9 technology. 2017 , 599, 1-18		90

120	Gene Editing: A New Tool for Viral Disease. 2017 , 68, 401-411		21
119	Alpha-helical HEAT-like Repeat Proteins (Rep) Selected as Interactors of HIV-1 Nucleocapsid Negatively Interfere with Viral Genome Packaging and Virus Maturation. <i>Scientific Reports</i> , 2017 , 7, 16335	4.9	6
118	Synthetic biology strategies towards the development of new bioinspired technologies for medical applications. 2017 , 451-497		4
117	CRISPR/Cas9-mediated deletion of EcMIH shortens metamorphosis time from mysis larva to postlarva of <i>Exopalaemon carinicauda</i> . 2018 , 77, 244-251		11
116	Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection. 2018 , 250, 21-30		24
115	CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection. 2018 , 29, 1264-1276		26
114	CRISPR genome editing and its medical applications. 2018 , 32, 286-292		10
113	Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency. 2018 , 10, 160-174		17
112	The Tools. 2018 , 41-56		
111	CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?. 2018 , 4, 871-880		9
110	Recent Advances in CRISPR-Cas9 Genome Editing Technology for Biological and Biomedical Investigations. 2018 , 119, 81-94		56
109	Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. 2018 , 66, 413-427		36
108	CRISPR-Cas based antiviral strategies against HIV-1. 2018 , 244, 321-332		55
107	CRISPR/Cas9 Genome Editing to Disable the Latent HIV-1 Provirus. <i>Frontiers in Microbiology</i> , 2018 , 9, 3107	5.7	19
106	The latest evidence for possible HIV-1 curative strategies. 2018 , 7, 212522		23
105	CRISPR/Cas9 system targeting regulatory genes of HIV-1 inhibits viral replication in infected T-cell cultures. <i>Scientific Reports</i> , 2018 , 8, 7784	4.9	55
104	Insights into the mechanisms underlying the inactivation of HIV-1 proviruses by CRISPR/Cas. 2018 , 520, 116-126		17
103	Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics. 2018 , 34, 950-960		19

102	Biomolecular Therapeutics for HIV. 2018 , 541-567		0
101	HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site. <i>Journal of Virology</i> , 2018 , 92,	6.6	20
100	Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir. 2018 , 16, 75		20
99	RNA Interference Therapies for an HIV-1 Functional Cure. <i>Viruses</i> , 2017 , 10,	6.2	22
98	CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy. <i>Viruses</i> , 2018 , 10,	6.2	26
97	CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development. <i>Viruses</i> , 2018 , 10,	6.2	16
96	Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies. <i>Viruses</i> , 2018 , 10,	6.2	14
95	Developmental progress of CRISPR/Cas9 and its therapeutic applications for HIV-1 infection. <i>Reviews in Medical Virology</i> , 2018 , 28, e1998	11.7	12
94	Barriers for HIV Cure: The Latent Reservoir. 2018 , 34, 739-759		37
93	Opportunities in biotechnology. 2018 , 282, 38-45		11
92	The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses. 2019 , 91, 1-13		8
91	Mechanisms for Controlling HIV-1 Infection: A Gene Therapy Approach. 2019 ,		1
90	Exploring the Potential of Cell-Free Protein Synthesis for Extending the Abilities of Biological Systems. 2019 , 7, 248		42
89	The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy. 2019 , 2019, 8458263		3
88	A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System. <i>Journal of NeuroImmune Pharmacology</i> , 2019 , 14, 578-594	6.9	3
87	A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections. 2019 , 96, 44-52		17
86	CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool. 2019 , 370, 725-735		16
85	Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019 , 9, 69	5.9	52

84	Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1 and TIGIT CD4 T Cells. <i>Journal of Virology</i> , 2019 , 93,	6.6	13
83	Isolation of gene-edited cells via knock-in of short glycoposphatidylinositol-anchored epitope tags. <i>Scientific Reports</i> , 2019 , 9, 3132	4.9	8
82	CRISPR-Cas based targeting of host and viral genes as an antiviral strategy. 2019 , 96, 53-64		10
81	CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. 2019 , 24,		23
80	CRISPR to fix bad blood: a new tool in basic and clinical hematology. 2019 , 104, 881-893		15
79	HIV cure strategies: a complex approach for a complicated viral reservoir?. 2019 , 14, 5-8		10
78	Emerging CRISPR/Cas9 applications for T-cell gene editing. 2019 , 3, 261-275		1
77	Nucleic acid testing and molecular characterization of HIV infections. 2019 , 38, 829-842		15
76	Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patients. <i>Scientific Reports</i> , 2019 , 9, 17088	4.9	15
75	Functional cure of HIV: the scale of the challenge. 2019 , 19, 45-54		54
74	Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech. <i>Molecular Therapy - Nucleic Acids</i> , 2019 , 14, 212-238	10.7	25
73	Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs. <i>Journal of NeuroImmune Pharmacology</i> , 2019 , 14, 68-93	6.9	1
72	Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome. <i>Reviews in Medical Virology</i> , 2019 , 29, e2009	11.7	11
71	Applications of genome editing in pet world. 2020 , 151-162		1
70	Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Genome Editing Technology Against Emerging and Reemerging Virus. 2020 , 11-29		
69	Towards a novel therapy against AIDS. <i>Medical Hypotheses</i> , 2020 , 137, 109569	3.8	4
68	Advances toward Curing HIV-1 Infection in Tissue Reservoirs. <i>Journal of Virology</i> , 2020 , 94,	6.6	23
67	CRISPR technology for genome editing. 2020 , 59-69		4

66	CRISPR-Cas13a Inhibits HIV-1 Infection. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 21, 147-155	10.7	21
65	Defective HIV-1 envelope gene promotes the evolution of the infectious strain through recombination in vitro. <i>BMC Infectious Diseases</i> , 2020 , 20, 569	4	0
64	Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF- κ B Binding Sites. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 21, 965-982	10.7	7
63	CRISPR Genome Editing Applied to the Pathogenic Retrovirus HTLV-1. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 580371	5.9	1
62	Multiplexed -Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape. <i>Viruses</i> , 2020 , 12,	6.2	2
61	TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 175	5.9	7
60	Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells. <i>Scientific Reports</i> , 2020 , 10, 9617	4.9	18
59	Prevention of Avian Retrovirus Infection in Chickens Using CRISPR-Cas9 Delivered by Marek's Disease Virus. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 21, 343-353	10.7	5
58	CRISPR-Cas9 for therapy: the challenges and ways to overcome them. 2020 , 101-110		
57	CRISPR-Cas13a Cleavage of Dengue Virus NS3 Gene Efficiently Inhibits Viral Replication. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 19, 1460-1469	10.7	23
56	An introduction to genome editing CRISPR-Cas systems. 2020 , 1-13		4
55	Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020 , 18, 532-557	6.4	32
54	Marek's disease virus as a CRISPR/Cas9 delivery system to defend against avian leukosis virus infection in chickens. <i>Veterinary Microbiology</i> , 2020 , 242, 108589	3.3	3
53	CRISPR/Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity. <i>IUBMB Life</i> , 2020 , 72, 1603-1621	4.7	10
52	CRISPR/Cas gene therapy. <i>Journal of Cellular Physiology</i> , 2021 , 236, 2459-2481	7	34
51	An introduction and use of the CRISPR-Cas systems. <i>Progress in Molecular Biology and Translational Science</i> , 2021 , 179, 1-10	4	0
50	Modulating Cas9 activity for precision gene editing. <i>Progress in Molecular Biology and Translational Science</i> , 2021 , 181, 89-127	4	
49	Exonic Disruption Facilitates Antiviral CRISPR-Cas9 Activity for Multistrain HIV-1 Elimination.		

48	CRISPR/Cas technology as a promising weapon to combat viral infections. <i>BioEssays</i> , 2021 , 43, e20003154.1		9
47	Computational Design of gRNAs Targeting Genetic Variants Across HIV-1 Subtypes for CRISPR-Mediated Antiviral Therapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 593077	5.9	0
46	The Interplay of HIV and Autophagy in Early Infection. <i>Frontiers in Microbiology</i> , 2021 , 12, 661446	5.7	7
45	Current Status of Approaches to Eradicate HIV Infection. 1-27		
44	Detect and destroy: CRISPR-based technologies for the response against viruses. <i>Cell Host and Microbe</i> , 2021 , 29, 689-703	23.4	13
43	Inactivation of Latent HIV-1 Proviral DNA Using Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Treatment and the Assessment of Off-Target Effects. <i>Frontiers in Microbiology</i> , 2021 , 12, 629153	5.7	0
42	Therapeutic Genome Editing and In Vivo Delivery. <i>AAPS Journal</i> , 2021 , 23, 80	3.7	
41	Inducible HIV-1 Reservoir Quantification: Clinical Relevance, Applications and Advancements of TILDA. <i>Frontiers in Microbiology</i> , 2021 , 12, 686690	5.7	0
40	Could gene therapy cure HIV?. <i>Life Sciences</i> , 2021 , 277, 119451	6.8	3
39	Efficient inhibition of HIV using CRISPR/Cas13d nuclease system.		0
38	The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 590989	5.9	3
37	Off-Target Analysis in Gene Editing and Applications for Clinical Translation of CRISPR/Cas9 in HIV-1 Therapy. <i>Frontiers in Genome Editing</i> , 2021 , 3, 673022	2.5	5
36	Efficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System. <i>Viruses</i> , 2021 , 13,	6.2	3
35	Targeting and Understanding HIV Latency: The CRISPR System against the Provirus. <i>Pathogens</i> , 2021 , 10,	4.5	1
34	Applications of CRISPR as a potential therapeutic. <i>Life Sciences</i> , 2021 , 284, 119908	6.8	12
33	A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure. <i>Current HIV Research</i> , 2021 , 19, 14-26	1.3	2
32	CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. <i>Computational and Structural Biotechnology Journal</i> , 2020 , 18, 2401-2415	6.8	25
31	Mutagenic repair of double-stranded DNA breaks in vaccinia virus genomes requires cellular DNA ligase IV activity in the cytosol. <i>Journal of General Virology</i> , 2018 , 99, 790-804	4.9	7

30	The multifaceted nature of HIV latency. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3381-3390	15.9	19
29	CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. <i>PLoS ONE</i> , 2015 , 10, e0136046	4.7	59
28	Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape. <i>PLoS Pathogens</i> , 2016 , 12, e1005953	7.6	16
27	A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness. <i>Acta Virologica</i> , 2019 , 63, 129-138	2.2	2
26	CRISPR/Cas system: An emerging technology in stem cell research. <i>World Journal of Stem Cells</i> , 2019 , 11, 937-956	5.6	14
25	Recent findings and applications of biomedical engineering for COVID-19 diagnosis: a critical review. <i>Bioengineered</i> , 2021 , 12, 8594-8613	5.7	4
24	Viral diversity is an obligate consideration in CRISPR/Cas9 designs for HIV cure.		
23	Unique natural and adaptive response mechanisms to control and eradicate HIV infection. <i>AIMS Allergy and Immunology</i> , 2018 , 2, 113-125	0.5	
22	Durable Control of HIV-1 Using a Staphylococcus aureus Cas9-Expressing Lentivirus Co-Targeting Viral Latency and Host Susceptibility.		
21	Introduction to Synthetic Biology. 2020 , 1-15		
20	The CRISPR/Cas9 genome editing methodology as a weapon against human viruses. <i>Discovery Medicine</i> , 2015 , 19, 255-62	2.5	46
19	The latest science from the IAS Towards an HIV Cure Symposium: 16-17 July 2016, Durban, South Africa. <i>Journal of Virus Eradication</i> , 2016 , 2, 235-241	2.8	1
18	CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination. <i>EBioMedicine</i> , 2021 , 73, 103678	8.8	1
17	CRISPR-Cas Technology: Emerging Applications in Clinical Microbiology and Infectious Diseases. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
16	The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy. <i>Journal of Advanced Research</i> , 2021 ,	13	0
15	Updates on CRISPR-based gene editing in HIV-1/AIDS therapy.. <i>Virologica Sinica</i> , 2022 , 37, 1-1	6.4	1
14	So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.. <i>Viruses</i> , 2022 , 14,	6.2	0
13	Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy.. <i>Methods in Molecular Biology</i> , 2022 , 2407, 429-445	1.4	0

12	An introduction to advanced technologies in synthetic biology. 2022 , 1-9		
11	Therapeutic Application of Genome Editing Technologies in Viral Diseases. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5399	6.3	0
10	Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12,	5.9	1
9	CRISPR-Cas-Based Gene Therapy to Target Viral Infections. 2022 , 85-125		0
8	Pitfalls of Antiretroviral Therapy: Current Status and Long-Term CNS Toxicity. <i>Biomolecules</i> , 2022 , 12, 894	5.9	0
7	Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication. 2022 , 14, 1902		0
6	Inhibition of HIV-1 replication using the CRISPR/cas9-no NLS system as a prophylactic strategy. 2022 , 8, e10483		0
5	Challenges and hopes in CRISPR CAS technology in future. 5-12		0
4	Advances in CRISPR therapeutics.		0
3	CRISPR/Cas9: a tool to eradicate HIV-1. 2022 , 19,		0
2	A CRISPR-Cas Cure for HIV/AIDS. 2023 , 24, 1563		0
1	Recent advances in nanocomposite-based delivery systems for targeted CRISPR/Cas delivery and therapeutic genetic manipulation.		0